Everyone involved in the life sciences innovation and entrepreneurship ecosystem of MA should attend. This event is designed to inspire researchers, innovators, entrepreneurs, post-docs and graduate students throughout the Commonwealth to take their ideas to commercialization faster - whether it is through management, funding or partnerships. It is an opportunity to meet serial entrepreneurs, venture capitalists, angel investors as well as many top leaders who have created companies or commercialized technologies coming out of laboratories and ideas. The day's event will bring together the Commonwealth's leading researchers and innovators, along with top-tier management of biotech, pharma and medtech companies as well as the key life sciences funding sources including angels, foundations, venture capitalists, grant experts, Federal Government and philanthropists.
The day's events will bring together the Commonwealth's leading researchers and innovators, along with top-tier management of biotech, pharma and medtech companies and the key life sciences funding sources including angels, foundations, venture capitalists, grant experts, Federal Government representatives, state elected officials, state program managers, and philanthropists focused on cures. We'll supplement this high-octane group with consultants, lawyers and sector experts who can help you find answers faster.
Nobel Laureate, Professor, University of
Craig C. Mello, PhD, is the Blais University Chair in Molecular Medicine at the University of Massachusetts Medical School and an Investigator of the Howard Hughes Medical Institute.
Dr. Mello and his colleague Andrew Fire, PhD, of
Dr. Mello holds a BS in Biochemistry from
Phillip A. Sharp, Ph.D.
Nobel Laureate, Professor, Massachusetts Institute of Technology
A world leader of research in molecular biology and biochemistry, Dr. Phillip A. Sharp is Institute Professor at the Massachusetts Institute of Technology.
Much of Dr. Sharp's scientific work has been conducted at MIT's Center for Cancer Research (now the Koch Institute), which he joined in 1974 and directed from 1985 to 1991. He subsequently led the Department of Biology from 1991 to 1999 before assuming the directorship of the McGovern Institute from 2000-2004. His research interests have centered on the molecular biology of gene expression relevant to cancer and the mechanisms of RNA splicing. His landmark achievement was the discovery of RNA splicing in 1977. This work provided one of the first indications of the startling phenomenon of "discontinuous genes" in mammalian cells. The discovery that genes contain nonsense segments that are edited out by cells in the course of utilizing genetic information is important in understanding the genetic causes of cancer and other diseases. This discovery, which fundamentally changed scientists' understanding of the structure of genes, earned Dr. Sharp the 1993 Nobel Prize in Physiology or Medicine. His lab has now turned its attention to understanding how RNA molecules act as switches to turn genes on and off (RNA interference). These newly discovered processes have revolutionized cell biology and could potentially generate a new class of therapeutics.
Dr. Sharp has authored over 350 scientific papers. He has received numerous awards and honorary degrees, and has served on many advisory boards for the government, academic institutions, scientific societies, and companies. His awards include the Gairdner Foundation International Award, General Motors Research Foundation Alfred P. Sloan, Jr. Prize for Cancer Research, the Albert Lasker Basic Medical Research Award, the National Medal of Science and the inaugural Double Helix Medal from CSHL. He is elected member of the National Academy of Sciences, the
A native of
In 1978 Dr. Sharp co-founded Biogen (now Biogen Idec), in 2002, he co-founded Alnylam Pharmaceuticals, an early-stage therapeutics company, and in 2006, he co-founded Magen Biosciences Inc., a biotechnology company developing agents to promote the health of human skin. He serves on the boards of all three companies.
Dr. Joshua Boger is the founder, President and Chief Executive Officer of Vertex Pharmaceuticals Incorporated. He has been the Company's CEO since 1992, and also served in the additional role of Chairman of the Board from 1997 until 2006. Dr. Boger served as Vertex's Chief Scientific Officer from 1989 until 1992 and has been a Director since Vertex's inception.
Dr. Boger holds a B.A. in chemistry and in philosophy from
Prior to founding Vertex in 1989, Dr. Boger held the position of Senior Director of Basic Chemistry at Merck Sharp & Dohme Research Laboratories in
J.J. Collins received a bachelor's degree in Physics (summa cum laude; class valedictorian) from the College of the Holy Cross in 1987 and a doctorate in Medical Engineering from the
Currently, Dr. Collins is a University Professor, Professor of Biomedical Engineering, and Co-Director of the Center for BioDynamics at
Dr. Collins is a scientific co-founder and chair of the scientific advisory board (SAB) of Cellicon Biotechnologies, Inc., and a scientific co-founder and chair of the SAB of Afferent Corp. He is also a member of the SAB of MannKind Corp. and Codon Devices, respectively. Dr. Collins' research focuses on developing nonlinear dynamical techniques and devices to characterize, improve and mimic biological function. His specific interests include: systems biology-reverse engineering naturally occurring gene regulatory networks, synthetic biology-modeling, designing and constructing synthetic gene networks, and developing noise-based sensory prosthetics.
Robert Coughlin is a former state representative and businessman. In his leadership role within Governor Deval Patrick's administration, he worked to retain and recruit life science organizations and other key businesses for the state. He is very familiar with all areas of the
A graduate of the
President & CEO, Tempo Pharmaceuticals, Inc. and Venture Partner, Polaris Ventures
Mr. Crane is currently President and CEO of Tempo Pharmaceuticals, Inc. He has also been a venture partner at Polaris Ventures since April of 2002.
From 2002 until 2006, Mr. Crane was President and CEO of Momenta Pharmaceuticals. He joined Momenta as the fifth employee and built the company into a public company, creating an advanced and diversified pipeline, entering into two strategic collaborations with the Sandoz division of Novartis, and raising $275 million. Prior to this, Mr. Crane was senior vice president of global corporate development at Millennium Pharmaceuticals, where he was responsible for leading Millennium's strategic partnering, mergers and acquisitions, and licensing activities, generating over $2 billion in partner funding and acquiring 19 development stage products. Prior to Millennium, Mr. Crane was a marketing executive at Dupont-Merck and a consultant with the Boston Consulting Group and Arthur D. Little.
He serves on the boards of Momenta Pharmaceuticals, Sirtris Pharmaceuticals, Adnexus and Vaccinex and is a member of the board of Children's Hospital Trust and a founder and member of the board of the Autism Consortium.
He received his M.B.A. in 1992 and his B.A. summa cum laude and M.A. in 1986, all from
John V. Frangioni is an attending physician and Associate Professor in the Division of Hematology/Oncology, Department of Medicine, at the Beth Israel Deaconess Medical Center. He is also an Associate Professor of Radiology in the Department of Radiology at the BIDMC. His academic appointments as an Associate Professor of Medicine and an Associate Professor of Radiology are at Harvard Medical School.
His academic training includes an Engineering Sciences degree from
Kalpana Gupta leads IAVI's R&D efforts on identification of new vaccine technologies and frequently participates in IAVI's policy initiatives focused on accelerating R&D and access. She was responsible for setting up the auditing process for the selection of international sites where IAVI is considering large-scale clinical trials of the most promising AIDS vaccines. Prior to joining IAVI, she worked for the WHO-UNAIDS HIV Vaccine Initiative in
Donald E. Ingber, M.D., Ph.D
Professor, Harvard Medical School and Children's Hospital Boston
Donald E. Ingber is a member of the Vascular Biology Program at Children's Hospital, Center for Nanoscale Systems and
Ingber is also acting Co-Director of Harvard's Institute for Biologically Inspired Engineering, and Director at Children's
He also helped to found two biotechnology start-ups, and has consulted for multiple pharmaceutical, biotechnology, venture capital and private investment companies and New York Public Radio. Through interdisciplinary collaborations with experts in chemistry, physics, engineering, magnetics and optics, Ingber has helped to develop multiple new biotechnologies, including molecular self-assembly techniques to create defined cell culture microenvironments, micro- and nano-magnetic methods to probe and manipulate cell structure and function, and nanosurgical laser methodologies to selectively vaporize nanodomains within living cells.
Executive Director and Co-Founder, The Adenoid Cystic Carcinoma Research Foundation (ACCRF)
Jeffrey Kaufman is the Executive Director and Co-Founder of the ACCRF, a nonprofit organization formed in 2005 that manages and supports research into a rare malignancy of the head and neck. He leads a Research Agenda of basic and translational projects spanning institutions in the
Co-Founder, President and CEO, Confluent Surgical
Amar Sawhney, Ph.D. is one of the inventors of the hydrogel technology, which forms the core of Confluent's technology platform. His inventions have formed the basis for the founding of several medical device and biotechnology companies and their products. In addition, other companies that are pursuing technologies that have been co-invented by Dr. Sawhney include Access Closure, Inc. (ACI), Novacell, and Azopax. Dr. Sawhney holds over 55 patents and has authored over 100 publications and scientific abstracts. Prior to co-founding Confluent, Dr. Sawhney was Director and Technology Founder at Focal, Inc. (acquired by Genzyme). In addition to Confluent, he serves on the board of MarketRx Inc. (an Incept company specializing in sales and marketing effectiveness, planning, and analytical products and services) as well as ACI.
Dr. Jie Song is an assistant professor in the Departments of Orthopedics and Cell Biology at the University of Massachusetts Medical School. Her research interest is to design synthetic tissue grafts facilitating the repair and regeneration of musculoskeletal tissues. In addition to engineering the tissue grafts with proper structural and biochemical microenvironment, her research group is also integrating minimally invasive surgical handling characteristics into the materials design.
Dr. Song holds a BS in Chemistry (1995) from
Robert Tosti is a partner in the Intellectual Property, Patent Counseling & Prosecution, Intellectual Property Litigation, Trademark, Copyright & Advertising, Clean Technologies and Medical Device practice groups and a member of the Cooley Godward Kronish Litigation department. He joined the Firm in 2007 and is resident in the
His practice includes patent and trademark prosecution, portfolio development, licensing and the assessment and enforcement of intellectual property rights. Mr. Tosti is a registered patent attorney and has experience with a variety of technologies including software, business methods, semiconductors, networks and medical devices.
Mr. Tosti has been named as a Massachusetts Super Lawyer. Prior to joining Cooley, Mr. Tosti was a partner in the
Mr. Tosti received his law degree, cum laude, from
Ganesh Venkataraman Ph.D.
Senior Vice President & CSO, Momenta Pharmaceuticals, Inc.
Dr. Venkataraman is one of Momenta's scientific founders. Prior to founding Momenta, Dr. Venkataraman was a member of the MIT faculty where he pioneered research in the area of analytical techniques for complex carbohydrates. He also served as the Director of Bioinformatics for the Consortium for Functional Glycomics, a multi-million-dollar NIH initiative to study the role of complex sugars in biology.
Christoph Westphal, M.D., Ph.D.
CEO and Vice Chair, Sirtris Pharmaceuticals, Inc.
Christoph Westphal, M.D., Ph.D., co-founded Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT) and has served as Chief Executive Officer and Vice Chair since 2004. As CEO and Vice Chair, Dr. Westphal previously co-founded Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), and Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA). These three companies trade at a collective market cap of roughly $2 billion. Dr. Westphal received his M.D. from